Transdermal formulation of nicardipine hydrochloride

Details Transdermal formulation of nicardipine hydrochloride Transdermal formulation of nicardipine hydrochloride

1985-01-31

1987-01-20

Griffin, Ronald W.

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Polymer from ethylenic monomers only

514356, 514947, 604304, 604307, A61F 1300, A61K 970, A61L 1500

Patent

active

046379304

ABSTRACT:
A formulation is provided for the transdermal administration of nicardipine hydrochloride. The formulation is comprised of nicardipine hydrochloride dissolved or suspended in a mixed liquid composed of an urea and at least one compound selected from the group consisting of propylene glycol, a monohydric alcohol having 2 to 4 carbon atoms, lactic acid, thioglycol, a middle chain fatty acid glyceride and a sorbitan middle chain fatty acid ester compounded with a transdermal formulation base.

REFERENCES:
patent: 3485847 (1969-12-01), Bossert et al.
patent: 3644627 (1972-02-01), Bossert et al.
patent: 4551467 (1985-11-01), Wehinger et al.
"Goodman and Gilman's The Pharmacological Basis of Therapeutics", 6th Ed., MacMillan Publishing Co., pp. 819-828 (1980) (Goodman et al).
"Remington's Pharmaceutical Sciences", 16th Ed., Mack Publishing Company (Easton, Pa.), pp. 1520-1522 and 1261 (1980).

Affiliated with

Also associated with

Rating

Transdermal formulation of nicardipine hydrochloride does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transdermal formulation of nicardipine hydrochloride, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal formulation of nicardipine hydrochloride will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2134328